Samsrita Labs Ltd PE Ratio

Samsrita Labs PE Ratio

Image

Samsrita Labs Ltd

NSE: SAMSRITALABS

PE

-

Last updated on: Sep 07, 2026

Key Highlights

  • The P/E Ratio of Samsrita Labs Ltd is 0 as of 07 Sep 15:30 PM The P/E Ratio of Samsrita Labs Ltd changed from 28.5 on March 2022 to 0 on March 2026 . This represents a CAGR of -100.00% over 5 years .

Historical P/E Ratio of Samsrita Labs Ltd

No data available

Company Fundamentals for Samsrita Labs Ltd

Image

Samsrita Labs Ltd

NSE: SAMSRITALABS

Share Price

₹ -

Last updated on: Jan 01, 2026

Market Price of Samsrita Labs Ltd

1M

1Y

3Y

5Y

Monitoring Samsrita Labs Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
07 Sep 202612.21
04 Sep 202612.65
03 Sep 202612.38
02 Sep 202611.9
01 Sep 202612.13
31 Aug 202611.6
28 Aug 202611.05
27 Aug 202610.6
26 Aug 202610.81
25 Aug 202611.14

BlinkX Score for Samsrita Labs Ltd

Asset Value vs Market Value of Samsrita Labs Ltd

Market Value

0

Asset Value

0

* All values are in ₹ crores

Competitive Comparison of P/E Ratio

Company
leftMarket Capright
Samsrita Labs Ltd28.78
Adani Enterprises Ltd397367
Premier Energies Ltd45304
Aegis Logistics Ltd44596
Redington Ltd29035
Honasa Consumer Ltd15348

Key Valuation Metric of Samsrita Labs Ltd

X

Historical Market Cap of Samsrita Labs Ltd

No data available

* All values are in crore

Historical Revenue, EBITDA and Net Profit of Samsrita Labs Ltd

Revenue

EBITDA

Net Profit

No data available

* All values are in crore

Historical Dividend Payout of Samsrita Labs Ltd

No data available

* All values are in %

About Samsrita Labs Ltd

  • Samsrita Labs Limited was initially established as 'Dr Habeebullah Life Sciences Limited' on January 25, 1996.
  • The name of the Company was changed from Dr Habeebullah Life Sciences Limited to Samsrita Labs Limited on October 13, 2022.
  • Company, initially focused on three different verticals called, Stem cell related Hospitals, Molecular Diagnostics and R&D in New Drug Discovery but due to other reasons, aimed to shifting into Bio-pharma activities like Trading, Exports & Imports, manufacturing of Bulk drugs, APIs, Specialty drugs, R&D etc through joint ventures or associations or mergers or by its own.
  • The Company is engaged into the business of research & experimental development on natural sciences and engineering, including bio pharma and hospital services also. In 2017, the Company changed its Main Objects clauses by venturing into the business of Bio-Pharma and also entered the following areas like New Drug Discovery including New Molecular Entity (NME - Pro Drug); Clinical Research Organization (CRO) related activities; Stem Cell - Lab, Research and Therapy; Research and Development in Bio-technology; Consultancy Division and Pharmacy; Academic Services like Courses / Lectures / Seminars on Biotechnology, Pharma, Stem Cell Research and therapy, Clinical Research and animal studies etc.

Samsrita Labs Ltd News Hub

Samsrita Labs reports standalone net loss of Rs 0.09 crore in the June 2024 quarter

Net Loss of Samsrita Labs reported to Rs 0.09 crore in the quarter ended June 2024 as against net lo

Read more

12 Aug 24

Samsrita Labs to announce Quarterly Result

Samsrita Labs will hold a meeting of the Board of Directors of the Company on 12 August 2024. Powere

Read more

09 Aug 24

Samsrita Labs to hold AGM

Samsrita Labs announced that the 28th Annual General Meeting (AGM) of the company will be held on 21

Read more

02 Sept 24

Samsrita Labs reports standalone net loss of Rs 0.04 crore in the December 2024 quarter

Net Loss of Samsrita Labs reported to Rs 0.04 crore in the quarter ended December 2024 as against ne

Read more

06 Jan 25

Product Composition by Percentage (Revenue)

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions